- Allergy Therapeutics has entered into a co-development collaboration agreement with Ergomed for the clinical development of three OralVac immunotherapy products.

Allergy Therapeutics said its core focus remained the convenient short course subcutaneous immunotherapy (SCIT) products, with the OralVac sublingual products providing an alternative option for patients who prefer oral products.

Under the terms of the agreement, Ergomed will progress the clinical development of OralVac products for the treatment of grass pollen, tree pollen, and house dust mite allergies. The collaboration includes a future revenue share and reduced service fee.

Story provided by